Table II Additional glycosylation sites identified from ETD (or CID as indicated) spectra after exoglycosidase treatment

Glycosylation sites identified and the carbohydrate structure detected are printed in bold. Residues in parentheses represent the amino acid residues before and after the sequence stretch identified. They are included to demonstrate the extent of nonspecific cleavages.

Fibrinogen β chain(−)1<QFPT(GalNAc)DYDEGQDDRPK15(V)a
Insulin-like growth factor II precursor(R)93DVSASTTVLPDDVT(GalNAc)AYPVG111(K)+GalNAca
Apolipoprotein E precursor(A)19DMEGELGPEEPLTT(GalNAc)QQPR36(D)a
(L)303ALRPSPT(GalNAc)S(GalNAc)PPSENH316(−)
Inter-α-trypsin inhibitor, heavy chain H1 precursor(F)639MLQAS(GalNAc)QPAPT(GalNAc)HSSLDIK655(K)
Inter-α-trypsin inhibitor, heavy chain H4 precursor(L)680APAS(GalNAc)APSPTSGPGGASHDTDFR701(I)+GalNAc
(R)702IKGT(GalNAc)T(GalNAc)PT(GalNAc)ALPFAPVQAPSVILPLPGQSVDR731(I)
Fetuin-B precursor(N)281PSKTEELQQQNT(GalNAc)APTNSPTK300(A)+GalNAc
Plasma serine protease inhibitor precursor(K)25KKIQEVPPAVT(GalNAc)T(GalNAc)APPGSR42(D)
  • aIdentified from CID spectra.